中文         Site Map |
 
 
 
Chairman of Guilin Pharmaceutical was Invited to Attend MMV 10th Anniversary Conference
Date: Jul.12.2011
 
Mr. Yu Zhemin, Chairman of Guilin Pharmaceutical was invited as honorable guest to attend the 10th anniversary conference and 11th Annual Stakeholders' Meeting of Malaria Medicine Venture (MMV) in Dares Salaam, Tanzania from June 1st, 2011 to June 3rd, 2011.
 
MMV is a malaria medicine related researching NGO headquartered in Geneva, Switzerland who is focusing on funding and technical supporting for development of new malaria drugs. The organization is highly respected as one of the top R&D institutions in the field of malaria.
 
Since 2008, Guilin Pharmaceutical began to work together with MMV in the reconstruction project of artesunate for injection workshop  complied with international GMP standards. After three years’ hard work, Guilin's artesunate for injection product (Artesun®) was finally pre-qualified by WHO in Nov.5, 2010. The project was identified as one of the most important achievements in the ten-year history of MMV since its establishment in 2000. The cooperation between MMV and Guilin Pharma is also regarded as a successful model of win-win cooperation.
Therefore, Mr. Yu Zhemin was invited as MMV’s honorable guest to attend the celebration by MMV. Guilin pharma was also the only participant from the industry with such award to the celebration.
 
The MMV’s 10th anniversary invited not only head of NMCP of over 10 African countries, WHO officials, representatives of international NGOs and academic authorities of anti-malaria, but also His Excellency President Jakaya Kikwete of Tanzania. During the dinner party, His Excellency President Spoke highly of MMV’s contribution to global anti-malarial career, and particularly emphasized the epoch-making significance of MMV’s bringing artesunate for injection to malaria endemic countries like Tanzania.
 
In April 2011, The World Health Organization updated its Guidelines for the Treatment of Malaria to recommend "Artesunate for injection" as the first line and a golden standard treatment for severe malaria in both children and adults. One month after the new guideline’s publication, some African countries such as Uganda and Ghana have begun to adjust their “National Guidelines for the Treatment of severe Malaria” in accordance with WHO. At the same time, Médecins Sans Frontières (MSF), the famous international humanitarian relief agency, announced on its website that its procurement shift from quine to artesunate for injection to treat severe malaria from now on.
As the first and the only WHO prequalified artesunate for injection, Guilin’s Artesun was highly taken care of by most participants during the three-day meeting.

We believe that with the global promotion of “Treating severe malaria with artesunate for injection”, the new artesunate therapy will take place of traditional "Quinine therapy" soon in most malaria epidemic regions and will play a significant role in reducing malaria mortality of African children.

 

This site is published by Guilin Pharmaceutical (Shanghai) Corporation,        which is solely responsible for its content. All rights reserved.

© Guilin Pharmaceutical (Shanghai) Co., Ltd. 2017.